The ACME Laboratories has announced the start of commercial production at its state-of-the-art steroid and hormone facility in Dhamrai following successful completion of trial production.
The steroid and hormone facility is one of the three projects for which the company raised funds through initial public offering (IPO), said an official disclosure on Tuesday.
Recently, the company also started commercial production at its state-of-the-art Penicillin facility in Dhamrai following successful completion of trial production.
The ACME Laboratories, the country's oldest pharmaceutical company, raised Tk 4.09 billion from the public through IPO under the book-building method in early 2016.
The drug maker floated 50 million ordinary shares of Tk 10 each with a premium of Tk 67 for the general and affected investors and non-resident Bangladeshis.
On Wednesday, each ACME share traded between Tk 74.40 and Tk 76 on the Dhaka Stock Exchange (DSE) before closing at 74.70 on the day, losing 0.80 per cent over the previous session.
In the last one year, its share traded between Tk 69 and Tk 100.
The company disbursed 35 per cent cash dividend for the year ended on June 30, 2018.
The company's earnings per share (EPS) in nine months for July 2018-March 2019 stood at Tk 5.43 as against Tk 5.66 for July 2017-March 2018.
The net operating cash flow per share (NOCFPS) was Tk 5.15 for July 2018-March 2019 as against Tk 6.80 for July 2017-March 2018.
The net asset value (NAV) per share was Tk 85.32 as on March 31, 2019 and Tk 83.39 as on June 30, 2018.
The company's paid-up capital is Tk 2.11 billion and authorised capital is Tk 5.0 billion while the total number of securities is 211.60 million.
Sponsors hold 31.98 per cent stakes in the company while the institutions 31.26 per cent, foreign investors 0.82 per cent and the general public the remaining 35.94 per cent as of May 31, the DSE data show.